The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Use of circulating tumor DNA (ctDNA) to complement tumor tissue homologous recombination repair (HRR) gene alteration testing in TALAPRO-2, a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Arun  Azad

Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar

Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar

Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis

Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)

Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar

Karim  Fizazi

Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst)

Consulting or Advisory Role - Amgen (Inst); Arvinas; Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen Oncology (Inst); Macrogenics; MSD (Inst); Novartis (Inst); Orion; Pfizer (Inst); Sanofi (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Janssen; MSD; Pfizer

Nobuaki  Matsubara

Honoraria - Sanofi

Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Pfizer; Sanofi; Seagen

Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)

Peter C.C.  Fong

Consulting or Advisory Role - MSD

Travel, Accommodations, Expenses - Pfizer

Joan  Carles

Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZéneca; Bayer; Bristol-Myers Squibb; Johnson & Johnson/Janssen; MSD Oncology; Pfizer; Roche; Sanofi

Speakers' Bureau - Astellas Pharma; Bayer; Johnson & Johnson

Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); BN ImmunoTherapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera; Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen-Cilag International NV (Inst); Karyopharm Therapeutics (Inst); Laboratories Leurquin Mediolanum (Inst); Lilly (Inst); Medimmune (Inst); Millenium Pharamceuticals (Inst); Nanobiotix (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi Aventis GmbH (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)

Travel, Accommodations, Expenses - AstraZeneca; BMS; Ipsen; Roche

Neal D.  Shore

Employment - GenesisCare

Leadership - Alessa Therapeutics; Photocure

Consulting or Advisory Role - Abbvie; AIkido Pharma; Amgen; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clarity Pharmaceuticals; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Foundation Medicine; Genesis Cancer Care; Genzyme; Guardant Health; ImmunityBio; Incyte; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myovant Sciences; Myriad Genetics; NGM Biopharmaceuticals; Nonagen Bioscience; Novartis; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Photocure; PlatformQ Health; Profound Medical; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Sesen Bio; Speciality Networks; Telix Pharmaceuticals; Tempus; Tolmar; Urogen pharma; Vaxiion; Vessi Medical

Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer

Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow

Expert Testimony - Ferring

Other Relationship - Alessa Therapeutics; Photocure

Ugo  De Giorgi

Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; MSD; Novartis; Pfizer; PharmaMar; Roche

Research Funding - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst)

Robert J.  Jones

Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Elsevier; Ipsen; Janssen; Merck Serono; MSD Oncology; Novartis; Pfizer; QED Therapeutics; Roche/Genentech; Sanofi; WebMD

Consulting or Advisory Role - Myovant Sciences

Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Celgene; IPSEN; Janssen; Merck Serono; MSD Oncology; Pfizer

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Exelixis (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Janssen; MSD

Lawrence Ivan  Karsh

Stock and Other Ownership Interests  - Swan Valley Medical (I)

Honoraria - Astellas Pharma; AstraZeneca; Bayer; Dendreon; Janssen; Merck; Pfizer

Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Roche; Dendreon; Ferring; Janssen; Merck; Pfizer

Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Dendreon; Janssen; Myovant Sciences; Pfizer

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bioxell Pharma (Inst); Bristol-Myers Squibb/Sanofi (Inst); Dendreon (Inst); Exact Sciences (Inst); Ferring (Inst); FKD Therapies (Inst); Genomic Health (Inst); Hinova Pharmaceuticals (Inst); Janssen (Inst); KDx Diagnostics (Inst); Merck (Inst); Myovant Sciences (Inst); Pfizer (Inst); Tavanta Therapeutics (Inst); Vaxiion (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; dendreon; Janssen; Pfizer

Jae Young  Joung

Honoraria - Astellas Pharma; Johnson & Johnson/Janssen; Sanofi/Aventis

Andre P.  Fay

Honoraria - AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD; Novartis; Pfizer; Roche

Consulting or Advisory Role - AstraZeneca; Ipsen; Merck Sharp & Dohme; Novartis; Pfizer; Roche

Glenn  Liu

Employment - AIQ Solutions

Leadership - AIQ Solutions

Stock and Other Ownership Interests  - AIQ Solutions

Consulting or Advisory Role - Janssen medical Affairs

Research Funding - Johnson & Johnson (Inst); Madison Vaccines, Inc.; Novartis (Inst); Pfizer; TRACON Pharma

Patents, Royalties, Other Intellectual Property - I have patent pending titled "System and method for evaluation of disease burden" which provides a novel method to identify and quantitate treatment response. (Inst)

Steven M.  Yip

Stock and Other Ownership Interests  - Pfizer

Honoraria - Amgen; AstraZeneca; Bayer; BMS; Ipsen; Janssen; Merck; Novartis; Pfizer; Roche

Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bayer; Bms; EMD Serono; Ipsen; Janssen; Merck; Novartis; Pfizer; Roche

Speakers' Bureau - Janssen; Pfizer

Research Funding - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck

Travel, Accommodations, Expenses - Janssen; Pfizer

Stefanie  Zschaebitz

Honoraria - Amgen; Astellas Pharma; Bayer; BMS GmbH & Co. KG; Eisai Germany; Ipsen; Janssen Oncology; Merck Serono; MSD Oncology; Novartis; Pfizer (Inst)

Consulting or Advisory Role - Amgen; Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai; EUSA Pharma; Ipsen; Merck; MSD Oncology; Pfizer (Inst); Roche; Sanofi/Aventis (Inst)

Research Funding - Eisai (Inst)

Travel, Accommodations, Expenses - Amgen; Astellas Pharma; BMS GmbH & Co. KG; Ipsen; Janssen Oncology; Merck; Pfizer

Julia F.  Hopkins

Employment - Foundation Medicine

Stock and Other Ownership Interests  - Roche

Nicola  Di Santo

Employment - Pfizer

Stock and Other Ownership Interests  - Pfizer

Xun  Lin

Employment - Pfizer

Stock and Other Ownership Interests  - Pfizer

Marielena  Mata

Employment - Pfizer

Stock and Other Ownership Interests  - Pfizer

Douglas  Laird

Employment - Pfizer

Stock and Other Ownership Interests  - Pfizer

Neeraj  Agarwal

Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen

Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)